3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Infections
3
Prostatic Neoplasms
2
Pancreatic Cyst
2
Breast Neoplasms
2
Urinary Tract Infections
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Staphylococcal Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Neoplasms
1
Multiple Myeloma
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Leukemia, B-Cell
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Interventions
Radiosurgery
2
Filgrastim
2
pegfilgrastim
1
Paclitaxel
1
DAT protocol 1
1
Ciprofloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Early Stage Breast Cancer
×
Ciprofloxacin
×
Clear all
NCT02816112
2020-05-27
REaCT-TC2
Ottawa Hospital Research Institute
Phase 4
Completed
458 enrolled